Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Catalyst plans to use the net proceeds from the offering (i) to fund clinical studies of Firdapse® for the treatment of MuSK-antibody positive Myasthenia Gravis (MuSK-MG) and Spinal Muscular Atrophy (SMA), (ii) to fund pre-commercialization activities for Firdapse®, and (iii) for general corporate purposes.
The offering will be made pursuant to a prospectus supplement to Catalyst's prospectus, dated
When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities will be available on the Investor Relations section of the Company's website and on the
Catalyst is also developing CPP-115 to treat refractory infantile spasms, and possibly refractory Tourette's Disorder. CPP-115 has been granted
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including whether the offering described in this press release will be completed and those other factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2016, the preliminary prospectus supplement related to the proposed offering, and Catalyst's other filings with the
Brian Korb The Trout Group LLC(646) 378-2923 email@example.com Company Contact Patrick J. McEnany Catalyst PharmaceuticalsChief Executive Officer (305) 420-3200 firstname.lastname@example.org Media Contacts David Schull Russo Partners(212) 845-4271 (212) 845-4272 email@example.com
News Provided by Acquire Media